Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $242

Author: Benzinga Newsdesk | October 20, 2025 08:34am

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $227 to $242.

Posted In: ABBV